Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Nontraumatic osteonecrosis of the femoral head (ONFH) is a progressive disease in young adults producing substantial morbidity and frequently resulting in total hip arthroplasty. Although hip-preserving surgical procedures represent the current mainstay of treatment for early disease, medical therapies targeting specific pathways in the ONFH pathogenesis could help prevent disease progression while producing less morbidity. Acetylsalicylic acid (ASA) is a promising alternative to other therapies for ONFH owing to its anti-inflammatory and antithrombotic mechanisms of action and its relatively benign side effect profile. METHODS: We followed a prospective cohort of 10 patients (12 hips) with precollapse ONFH who were given ASA to prevent disease progression. Their outcomes were compared with those of a historic control group taken from the literature. RESULTS: Progression occurred in 1 of 12 (8%) patients taking ASA compared with 30 of 45 (66.6%) controls (p = 0.002) at a mean follow-up of 3.7 years. Patients taking ASA also tended to exhibit decreased femoral head involvement at the end of therapy. CONCLUSION: This hypothesis-generating study leads us to believe that ASA may be a simple and effective treatment option for delaying disease progression in patients with early-stage ONFH.

publication date

  • June 1, 2015

Research

keywords

  • Anti-Inflammatory Agents, Non-Steroidal
  • Aspirin
  • Femur Head Necrosis

Identity

PubMed Central ID

  • PMC4447515

Scopus Document Identifier

  • 84937196702

Digital Object Identifier (DOI)

  • 10.1503/cjs.016814

PubMed ID

  • 26011853

Additional Document Info

volume

  • 58

issue

  • 3